Upsher-Smith Laboratories LLC, a United States-based pharmaceutical company, has signed a collaboration agreement with United States-based AmbioPharm Inc to produce and market Corticotropin Injection in the United States, it was reported on Friday.
According to the terms of the contract, Upsher-Smith is submitting the New Drug Application (NDA) for Corticotropin Injection to the United States Food and Drug Administration (FDA) and will market and distribute the product under its own label in the United States, after US FDA approval.
AmbioPharm is to produce the active pharmaceutical ingredient exclusively for Upsher-Smith. A contract manufacturing organisation is to provide Upsher-Smith with the finished product for sale in the United States.
Financial terms of the deal were not revealed.
Organon licenses MIUDELLA IUD from Sebela Pharmaceuticals
Gilead to acquire Arcellx to gain full control of anito-cel
Novo Nordisk's CagriSema achieves 23% weight loss but misses primary endpoint in REDEFINE 4 trial
AbbVie's VENCLEXTA (venetoclax) and acalabrutinib combination receives US FDA approval to treat CLL
Vanda Pharmaceuticals' BYSANTI (milsaperidone) tablets receive US FDA approval
FDA approves Genentech oral Venclexta plus AstraZeneca's Calquence combination for first-line CLL
EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer
Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons
Hansa's imlifidase Biologics License Application accepted by FDA
Novartis reports positive Phase III results for remibrutinib in chronic inducible urticaria
Cambridge Cognition expands into India through Ivory commercialisation agreement
HanchorBio's HCB101 receives US FDA Orphan Drug Designation in gastric cancer
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
MEDIPOST files IND amendment to start Phase III trial for knee osteoarthritis therapy